Integrative Biology & Medicine to motivate collaboration among biologists and to share transdisciplinary integrative thinking to unravel the core principal mechanisms and process in biology and medicine to understanding cellular and molecular mechanisms related to health and disease. Integrative Biology make a label of choice for consideration, to address and generates new information and new ideas by bringing various expertise to complications, so that individual and institutional expertise becomes wide-ranging and more examining as a consequence
As the name "Integrative Biology" reproduces belief that the study of biological systems is best approached by incorporating many discernments like Cell Biology, Molecular biology, Genetic Engineering and rDNA Technology, Computational Biology & Bioinformatics, Systems Biology, Developmental Biology, Structural biology, Bio-Engineering, Genomics, Cancer Biology, Biophysics. We bring together an assortment of disciplines that complement one another to unravel the complexity of biology. The principle includes anatomy, physiology, cell biology, biochemistry and biophysics, and covers animals, human and microorganisms. Our comprehensive of expertise includes: cell biologist, geneticists, physiologists, molecular biologist, computational biologist, systems biologists, structural biologist, and expert in bioinformatics, biophysicists and biotechnologist.
Evolutionary developmental biology (evo-devo) has proficient affected transformations since its emergence as a distinct discipline. This paper aims to highlight the scope, power, and future promise of evo-devo to transform and unify diverse aspects of biology. We articulate key questions at the core of eleven biological disciplines-from Evolution, Development, Paleontology, and Neurobiology to Cellular and Molecular Biology, Quantitative Genetics, Human Diseases, Ecology, Agriculture and Science Education, and lastly, Evolutionary Developmental Biology itself-and discuss why evo-devo is uniquely situated to substantially improve our ability to find meaningful answers to these fundamental questions. We speculate that the tools, concepts, and ways of thinking developed by evo-devo have insightful potential to advance, integrate, and unify biological sciences as well as inform policy decisions and illuminate science education. We look to the next generation of evolutionary developmental biologists to help shape this process as we confront the scientific challenges of the 21st century.
The universal market for Integrative Biology is assessed to reach USD 22.1 billion in 2020, increasing at an assessed CAGR of 10.3% from 2014 to 2020.permitting to a new study by Grand View Research, Inc. A part of integrative biology, which is Genomics play an commanding role in the field of infectious disease testing by enabling the use of fast and effective result transcription molecular diagnostic tests. This, coupled with growing prevalence of infectious diseases and hospital acquired infections is expected to drive market growth during the estimate period. Other driving factors for this market include decreasing prices of DNA sequencing, increasing demand for genome analysis in animal and plant feedstock, general presence of both private and public external funding programs and growing patient responsiveness levels. In addition, occurrence of unused growth opportunities in emerging countries such as India, Brazil and China and the increasing health awareness are expected to serve this market as future growth opportunities.
Major Biological Associations Around The Globe
Total Number Of Employees For Biotech Sectors
Universities And Research Centers In Berlin
Glance At German Market Of Integrative Biology
For the first time ever, the industry cracked the sales mark of €3bn in turnover generated. Compared to last year, this was an increase of 5.8%. With a total of almost 17,930, there were more employees than ever before working in the biotech industry (2013: 16950). And for the first time since 2008, spending on research and development (R&D) increased rather than decreased and is now at €954m (+ 6.2%). Investments mirrored the growth trend: around €445m was invested in German biotech companies compared to €401m the year before. Private firms raised a total of €172m in 18 rounds of financing, which marks an increase of 26% compared to 2015. Nevertheless, the interest from big business in biotech products remains steady, not only in the healthcare industry but increasingly also in the area of the bio economy.